CN105592861A - 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途 - Google Patents

抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途 Download PDF

Info

Publication number
CN105592861A
CN105592861A CN201480054398.5A CN201480054398A CN105592861A CN 105592861 A CN105592861 A CN 105592861A CN 201480054398 A CN201480054398 A CN 201480054398A CN 105592861 A CN105592861 A CN 105592861A
Authority
CN
China
Prior art keywords
conjugate
purposes
antibody
group
seqidno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480054398.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿萨杜里安
D·米格纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN105592861A publication Critical patent/CN105592861A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480054398.5A 2013-08-02 2014-07-30 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途 Pending CN105592861A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306119 2013-08-02
EP13306119.2 2013-08-02
PCT/EP2014/066345 WO2015014879A1 (en) 2013-08-02 2014-07-30 Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
CN105592861A true CN105592861A (zh) 2016-05-18

Family

ID=49036539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480054398.5A Pending CN105592861A (zh) 2013-08-02 2014-07-30 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途

Country Status (12)

Country Link
US (1) US20160347856A1 (https=)
EP (1) EP3027218A1 (https=)
JP (1) JP2016525560A (https=)
KR (1) KR20160035600A (https=)
CN (1) CN105592861A (https=)
AU (1) AU2014298514A1 (https=)
CA (1) CA2919932A1 (https=)
EA (1) EA201690321A1 (https=)
IL (1) IL243843A0 (https=)
MX (1) MX2016001541A (https=)
TW (1) TW201605479A (https=)
WO (1) WO2015014879A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105997942A (zh) * 2016-06-24 2016-10-12 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999604B (zh) * 2014-09-02 2021-08-03 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
GB201506388D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
CN112105384B (zh) * 2017-01-18 2024-08-23 苏州启航纳米药物有限公司 癌糖肽的单克隆和人源化抗体
WO2019030284A1 (en) * 2017-08-09 2019-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
MX2021005116A (es) * 2018-11-02 2021-07-15 Cytomx Therapeutics Inc Anticuerpos activables anti-cd166 y metodos de uso de estos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1922199A (zh) * 2003-07-21 2007-02-28 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
CN101242855A (zh) * 2005-08-22 2008-08-13 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321704A1 (en) * 1998-02-25 1999-09-02 Takeo Omura Remedies for corneal epithelium disturbance
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1922199A (zh) * 2003-07-21 2007-02-28 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
CN101242855A (zh) * 2005-08-22 2008-08-13 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105997942A (zh) * 2016-06-24 2016-10-12 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
CN105997942B (zh) * 2016-06-24 2019-01-29 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用

Also Published As

Publication number Publication date
WO2015014879A1 (en) 2015-02-05
EP3027218A1 (en) 2016-06-08
TW201605479A (zh) 2016-02-16
US20160347856A1 (en) 2016-12-01
EA201690321A1 (ru) 2016-12-30
MX2016001541A (es) 2016-08-18
IL243843A0 (en) 2016-04-21
KR20160035600A (ko) 2016-03-31
JP2016525560A (ja) 2016-08-25
WO2015014879A9 (en) 2015-11-19
AU2014298514A1 (en) 2016-03-10
CA2919932A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
CN105592861A (zh) 抗Muc1类美登素免疫偶联抗体用于治疗实体瘤的用途
IL299368A (en) A combination of an antibody-drug conjugate and an ATR inhibitor
US20230256110A1 (en) Combination of antibody-drug conjugate and atm inhibitor
US20210100913A1 (en) Activatable anti-cd166 antibodies and methods of use thereof
CN103145844B (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
BR112021008526A2 (pt) anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
US20220233705A1 (en) Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
JP5908972B2 (ja) 新規な抗原結合タンパク質
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
JP7829605B2 (ja) コネキシン４３抗体およびその使用
SA516371557B1 (ar) عوامل سامة للخلايا ثنائية الوظيفية
BR112020002368A2 (pt) conjugados anticorpo-medicamento tendo alta tolerabilidade in vivo
JP2017507905A (ja) Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
CN109147874A (zh) 用于配制抗体药物缀合物组合物的方法
TW202216212A (zh) 抗體-藥物結合物之製造方法
TW202333797A (zh) 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
CN118806923A (zh) 西妥昔单抗-ir700偶联物组合物
JP2022546387A (ja) 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用
CN120826244A (zh) 含有抗ceacam5抗体-药物缀合物、抗vegfr-2抗体和抗pd1/pd-l1抗体的抗肿瘤组合
TW202216207A (zh) 抗體-藥物結合物及cdk9抑制劑之組合
CN108472372A (zh) 结合不动杆菌的抗体结合剂及其用途
US20240100053A1 (en) Pharmaceutical composition
JP2021165268A (ja) シンデカン−１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質を含む医薬組成物
JP2022514148A (ja) シンデカン－１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質
HK40100613A (zh) 连接蛋白43抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160518

WD01 Invention patent application deemed withdrawn after publication